Researchers careful to state that the long-term outcome/efficacy of the immune response to the Oxford vaccine will be known after the Phase 3 arm of the trial. Great science but verification required.

Dr. Barry Dworkin

Medical Mythbusting Commentary for July 21, 2020

Researchers careful to state that the long-term outcome/efficacy of the immune response to the Oxford vaccine will be known after the Phase 3 arm of the trial. Great science but verification required. Play Now | Play in Popup | Download

Source:
Coronavirus: Oxford vaccine triggers immune response

Reference:

Safety and immunogenicity of the ChAdOx1 nCoV-19
vaccine against SARS-CoV-2: a preliminary report of
a phase 1/2, single-blind, randomised controlled trial

Related posts:

  1. A Phase-1 vaccine study result should not be used to extrapolate efficacy. It is designed to determine the vaccine’s safety profile. Patience required for the results of the next two trial phases to truly answer the efficacy question.
  2. No hype, no promises but Oxford coronavirus vaccine research is moving ahead with larger scale human trials
  3. Phase one trial of Alzheimer's vaccine study demonstrates safety; efficacy studies to follow
  4. Vaccine trial clinical investigators are worried that participants are MIA
Bitnami